Surveillance for Guillain-Barré syndrome after 2015–2016 and 2016–2017 influenza vaccination of Medicare beneficiaries

Highlights•No influenza vaccine had excess Guillain-Barré syndrome (GBS) risk 1–42 days post-vaccination. •All seasonal influenza vaccines had GBS risk within expected range, 8–21 days post-vaccination. •The high dose influenza vaccine had GBS risk within expected range, 8–21 days post-vaccination....

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2019-10, Vol.37 (43), p.6543-6549
Main Authors: Arya, Deepa P, Said, Maria A, Izurieta, Hector S, Perez-Vilar, Silvia, Zinderman, Craig, Wernecke, Michael, Alexander, Michael, White, Taylor, Su, I-Hsuan, Lufkin, Bradley, MaCurdy, Thomas, Kelman, Jeffrey, Forshee, Richard
Format: Article
Language:English
Subjects:
Allergy and Immunology
Antigens
Beneficiaries
Collaboration
Demyelinating diseases
Demyelination
Dosage
Flu
Government programs
Guillain-Barre syndrome
Guillain-Barré syndrome
High dose influenza vaccine
Immunization
Infections
Influenza
Males
Medicare
Risk management
Seasons
Surveillance
Swine
Swine flu
Vaccine
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights•No influenza vaccine had excess Guillain-Barré syndrome (GBS) risk 1–42 days post-vaccination. •All seasonal influenza vaccines had GBS risk within expected range, 8–21 days post-vaccination. •The high dose influenza vaccine had GBS risk within expected range, 8–21 days post-vaccination. •Standard dose influenza vaccines had no excess GBS risk 8–21 days post-vaccination. •Difference in GBS risk after different vaccine types is hypothesis-generating.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.08.045